Latest News

Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares

BEIJING–(BUSINESS WIRE)–Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today provided an update for shareholders with regards to the exchange (the “Exchange”) of preferred share purchase rights (the “Rights”) for the Company’s Common Shares and Series B Convertible Preferred Shares (the “Exchange Shares”), originally announced on February 22, 2019, by press release. On April 4, 2019, the Eastern Caribbean Supreme Cour

Source link

Related posts

Initiatives led by pharmacists can contribute to the prevention of cardiovascular disease


High levels of screen use associated with symptoms of anxiety in adolescence


Latin America 3D Cell Culture Market 2019-2027 – Increasing Usage of 3D Cell Culture in Organ Transplantation & Drug Screening Presents Lucrative Opportunities –


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy